Hamilton Kirsty R, Lee Sharon Si, Urquhart James C, Jonker Benjamin P
Department of Neurosurgery, Sir Charles Gardner Hospital, Hospital Ave, Nedlands, WA 6009, Australia.
Department of Neurosurgery, Perth Children's Hospital, 15 Hospital Ave, Nedlands, WA 6009, Australia.
J Clin Neurosci. 2019 May;63:168-175. doi: 10.1016/j.jocn.2019.02.001. Epub 2019 Mar 2.
The objective was to determine the impact of surgical resection and adjuvant therapies on survival in intramedullary ependymoma and astrocytoma. Secondary goals were to determine predictors of survival in surgical patients including histological grading, age and gender. Searching of Medline, Embase and Clinicaltrials.gov databases were performed. Multivariate analyses were performed for overall survival (OS) and progression-free survival (PFS) through Monte Carlo methods and Maximum Likelihood Estimation. 57 articles detail results for 3022 patients. Meta-analysis revealed the following factors to have a statistically significant effect on OS. Patients undergoing gross-total resection (GTR) are 5.37 times more likely to survive than patients with lesser volumes of tumor resected (HR for OS 1.68, p < 0.01). High-grade tumors were associated with a 14 times risk of death over low-grade tumors (HR for OS 2.64, p < 0.01). Radiation increased the risk of mortality in low-grade tumors (HR for OS 5.20, p < 0.01), but decreased mortality in high-grade lesions (HR for OS 2.46, p < 0.01). Adult patients were more likely to die from disease compared with pediatric patients by a factor of 1.6 (HR for OS 0.47, p < 0.01). In PFS, radiotherapy was associated with a reduced time to recurrence (HR for PFS 1.90, p < 0.01). There was a male predominance of 58%. Gender did not influence survival. 79% of patients demonstrated stable or improved functional neurological outcomes six months post-operatively. Our data indicates GTR improves OS in all tumor grades. Radiation improves OS only in the presence of high-grade histology. Advancing age and high-grade histology are negative prognostic indicators.
目的是确定手术切除和辅助治疗对髓内室管膜瘤和星形细胞瘤患者生存的影响。次要目标是确定手术患者生存的预测因素,包括组织学分级、年龄和性别。我们检索了Medline、Embase和Clinicaltrials.gov数据库。通过蒙特卡罗方法和最大似然估计对总生存期(OS)和无进展生存期(PFS)进行多变量分析。57篇文章详细报道了3022例患者的结果。荟萃分析显示以下因素对总生存期有统计学显著影响。接受全切除(GTR)的患者生存可能性是肿瘤切除量较少患者的5.37倍(OS的风险比为1.68,p<0.01)。高级别肿瘤的死亡风险是低级别肿瘤的14倍(OS的风险比为2.64,p<0.01)。放疗增加了低级别肿瘤的死亡风险(OS的风险比为5.20,p<0.01),但降低了高级别病变的死亡风险(OS的风险比为2.46,p<0.01)。与儿童患者相比,成年患者死于疾病的可能性高1.6倍(OS的风险比为0.47,p<0.01)。在无进展生存期方面,放疗与复发时间缩短相关(PFS的风险比为1.9